Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of CD34+ Cell Dose on ALC Following HDT and ASCT for Relapsed/Refractory DLBCL
NCT02570542Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Oct 2015
- Primary completion
- Oct 2027
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Progression-Free Survival. Started Oct 2015; status: active, not recruiting.
02
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT02570542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02570542.